{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irinotecan+%28Camptosar%29&page=7", "query": { "intervention": "Irinotecan (Camptosar)", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 921, "total_pages": 93, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irinotecan+%28Camptosar%29&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Irinotecan+%28Camptosar%29&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T11:49:58.565Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03692429", "title": "alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unresectable Metastatic Colorectal Cancer" ], "interventions": [ { "name": "CYAD-101", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celyad Oncology SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2018-11-28", "completion_date": "2036-02-17", "has_results": false, "last_update_posted_date": "2020-11-20", "last_synced_at": "2026-10-14T11:49:58.565Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03692429" }, { "nct_id": "NCT05332002", "title": "sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastro-Intestinal Cancer" ], "interventions": [ { "name": "Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2022-07-13", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-14T11:49:58.565Z", "location_count": 6, "location_summary": "Hamilton, New Jersey • Lakewood, New Jersey • Long Branch, New Jersey + 2 more", "locations": [ { "city": "Hamilton", "state": "New Jersey" }, { "city": "Lakewood", "state": "New Jersey" }, { "city": "Long Branch", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05332002" }, { "nct_id": "NCT00003345", "title": "Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 35, "start_date": "1997-10", "completion_date": "2001-10", "has_results": false, "last_update_posted_date": "2013-06-21", "last_synced_at": "2026-10-14T11:49:58.565Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003345" }, { "nct_id": "NCT04008030", "title": "A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 839, "start_date": "2019-08-05", "completion_date": "2027-03-23", "has_results": true, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-14T11:49:58.565Z", "location_count": 9, "location_summary": "Los Angeles, California • Sacramento, California • Denver, Colorado + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Arlington Heights", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04008030" }, { "nct_id": "NCT00089128", "title": "Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 16, "start_date": "2001-11", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2018-07-12", "last_synced_at": "2026-10-14T11:49:58.565Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089128" }, { "nct_id": "NCT00856830", "title": "Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "Extensive Stage Lung Cancer", "Chemonaive" ], "interventions": [ { "name": "Novel Drug Combination", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 30, "start_date": "2009-04", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2017-07-17", "last_synced_at": "2026-10-14T11:49:58.565Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Marietta, Georgia", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00856830" }, { "nct_id": "NCT01767194", "title": "Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ganglioneuroblastoma", "Recurrent Neuroblastoma" ], "interventions": [ { "name": "Dinutuximab", "type": "BIOLOGICAL" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 73, "start_date": "2013-02-12", "completion_date": "2022-09-30", "has_results": true, "last_update_posted_date": "2022-10-24", "last_synced_at": "2026-10-14T11:49:58.565Z", "location_count": 136, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Downey, California + 106 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01767194" }, { "nct_id": "NCT02423954", "title": "Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Pancreatic Cancer", "Renal Cell Cancer", "Non Small Cell Lung Cancer", "Colorectal Carcinoma", "Endometrial", "Uterine" ], "interventions": [ { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Irinotecan + capecitabine", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Western Regional Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2015-04", "completion_date": "2017-11-01", "has_results": false, "last_update_posted_date": "2018-07-02", "last_synced_at": "2026-10-14T11:49:58.565Z", "location_count": 1, "location_summary": "Goodyear, Arizona", "locations": [ { "city": "Goodyear", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02423954" }, { "nct_id": "NCT00561470", "title": "Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)", "type": "DRUG" }, { "name": "FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1226, "start_date": "2007-11", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2012-09-28", "last_synced_at": "2026-10-14T11:49:58.565Z", "location_count": 87, "location_summary": "Birmingham, Alabama • Muscle Shoals, Alabama • Hot Springs, Arizona + 68 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00561470" }, { "nct_id": "NCT00932438", "title": "Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colon Cancer With Metastases to the Liver" ], "interventions": [ { "name": "LC beads loaded with Irinotecan", "type": "DEVICE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "University of Louisville", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2009-06", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2021-06-11", "last_synced_at": "2026-10-14T11:49:58.565Z", "location_count": 9, "location_summary": "Huntsville, Alabama • Sacramento, California • Atlanta, Georgia + 5 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT00932438" } ] }